Chronic Obstructive Pulmonary Disease Treatment Market Key Findings with Top Companies AstraZeneca, Orion, Mylan N.V., Boehringer Ingelheim, Teva, GlaxoSmithKline, Novartis

Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic disease and symptoms include difficulty in breathing, mucus formation, wheezing, and others. COPD is a progressive lung disease, which includes chronic bronchitis, emphysema, and refractory asthma. Prime causes behind occurrence of chronic obstructive pulmonary disease include smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (rare form of COPD), and others. There are certain ways, by which complications can be prevented, as well as disease progression can be slowed down. These may include quitting smoking, adherence to the prescribed medication, and preventing associated co-morbidities such as flu, pneumonia, and others by vaccination against these diseases.

High incidence and prevalence of chronic obstructive pulmonary disease (COPD), coupled with awareness efforts carried out by individual organizations is expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period

According to National Center for Biotechnology Information (NCBI), in 2016, chronic obstructive pulmonary disease (COPD) was the third leading cause of death, globally. Furthermore, according Global Burden of Disease Study, COPD was prevalent in over 300 million people globally in 2013. Moreover, according to the same source, in European adults over 40 years of age, the prevalence of COPD ranged from 15-20%, in 2016. Moreover, according to the World Health Organization (WHO), Global Burden of Disease Study reports prevalence of 251 million cases of COPD, globally, in 2016. Increasing prevalence is expected to support the global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period. Organizations such as World Health Organization (WHO), COPD Foundation, American Thoracic Society, and Centers for Disease Control and Prevention (CDC) work towards raising COPD awareness in the population. National Institutes of Health (NIH) runs an initiative, ‘COPD Learn More Breathe Better’, and celebrates November as a national COPD awareness month. These factors are expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/2656

The global chronic obstructive pulmonary disease (COPD) treatment market size was valued at US$ 14,209.0 million in 2017, and is expected to witness a robust CAGR of 4.9% over the forecast period (2018–2026).

Verona Pharma commenced a phase IIb clinical trial to assess nebulized ensifentrine (RPL554), in combination with a long-acting bronchodilator to treat moderate to severe COPD, in May 2019. Novartis AG launched Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of COPD, in March 2019. Cipla launched Niveoli, beclomethasone-formoterol combination hydrofluoroalkane (HFA) inhaler for adults suffering from obstructive airway diseases (OAD) such as asthma and COPD, in April 2019. Moreover, manufacturers are also involved in improving overall COPD treatment paradigm by introducing medical devices, web-based applications, and other efforts to reduce the global burden of chronic obstructive pulmonary disease. For instance, Spire Health launched a study to develop new digital biomarkers that can predict exacerbations—and potentially hospitalizations—in patients with severe COPD, in May 2019. These factors are expected to support global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period.

However, development of new drugs is a challenging task and drug failures in clinical trials have affected growth of the market. For instance, asthma drug benralizumab failed to decrease annual COPD exacerbation rates for patients with moderate to very severe COPD, in May 2019. The Phase III, randomized, double-blind, placebo-controlled, parallel-group clinical trials GALATHEA and TERRANOVA evaluated the efficacy and safety of benralizumab for the prevention of exacerbations in patients with moderate to very severe COPD.

Some major players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/2656

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.